AzTrials
AzTrials

Multiple MyelomaPhase 2MOMENTUMNCT07284758

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 2 study testing Cemsidomide and Dexamethasone in people with Multiple Myeloma and Relapsed/Refractory Multiple Myeloma, run by C4 Therapeutics, Inc. at 60 sites in 6 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Cemsidomide and Dexamethasone
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
60 sitesin 6 countries
Study dates
18 Feb 2026to Mar 2030
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Be willing and able to provide signed informed consent for the study.
  • Age ≥ 18 years at the time of signed consent.
  • Subjects must have a documented diagnosis of MM and measurable disease at enrollment.
  • Received at least 3 prior anti-myeloma regimens (for a minimum of 2 or more consecutive cycles) that must have included an immunomodulatory drug (i.e., IKZF 1/3 degrader), a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy, unless not available per local standard of care.
  • Subjects need to have adequate organ function.
  • Toxicities from prior anticancer therapies must have resolved to baseline severity or CTCAE ≤ Grade 1.
Show all 10Show fewer
  • Female subjects may not be pregnant or intend to become pregnant, may not breastfeed or intend to breastfeed, or donate ova during their participation in this study until 30 days after the last dose of study treatment.
  • Male subjects must agree to use a condom when having intercourse with a person of childbearing potential during the Treatment Period and for at least 30 days after the last dose of study treatment.
  • Male subjects must refrain from donating sperm during the Treatment Period and for 30 days after discontinuation.
  • Subjects must refrain from donating blood during study treatment and for 30 days after discontinuation.

Who cannot join

  • Presence of myeloma in the central nervous system (CNS).
  • Subjects with any of the following:
  • Systemic light chain amyloidosis
  • Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome
  • Myelodysplastic syndrome (MDS).
  • Previously treated with cemsidomide.
Show all 12Show fewer
  • Clinically significant impaired cardiac function or cardiac disease.
  • Thromboembolic event within 3 months prior to enrollment.
  • Known malignancy other than study indication that has progressed or required treatment within the past 3 years.
  • Uncontrolled active bacterial, fungal, or viral infection.
  • Inability or difficulty swallowing tablets.
  • NOTE: Other inclusion/exclusion criteria may apply, per protocol.

Trial locations and contacts

60 sites in 6 countries. Contact the study team or a site near you to ask about taking part.

Study Medical Officer contact

(617) 231-0700

clinicaltrials@c4therapeutics.com

Patient Navigator contact

(888) 676-2873

support+c4@sparkcures.com

60 sites in 6 countries

United States25 sites, 25 recruiting

  • University of Michigan

    Ann Arbor, Michigan, 48109

    Matthew Piakno, MD

    Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia, 30322

    Nisha Joseph, MD

    Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02114

    Jessica Ligel, MD

    Not yet recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02114

    Paul Richardson, MD

    Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

    Andrew Yee, MD

    Recruiting

  • UNC Hospitals Adult Oncology Clinics

    Chapel Hill, North Carolina, 27514

    Sascha Tuchman, MD

    Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201

    Craig Cole, MD

    Recruiting

  • City of Hope

    Duarte, California, 91010

    Michael Rosenzweig, MD

    Recruiting

  • START Midwest

    Grand Rapids, Michigan, 49546

    Andrew Sochacki, MD

    Recruiting

  • Clearview Cancer Institute

    Huntsville, Alabama, 35805

    Lakshmikanth Katragadda, MD

    Recruiting

  • Indiana University Health

    Indianapolis, Indiana, 46202

    Attaya Suvannasankha, MD

    Recruiting

  • University of Iowa

    Iowa City, Iowa, 52242

    Christopher Strouse, MD

    Recruiting

  • Mayo Clinic - Florida

    Jacksonville, Florida, 32224

    Sikander Ailawadhi, MD

    Recruiting

  • University of Wisconsin - Carbone Cancer Center

    Madison, Wisconsin, 53792

    Natalie Callander, MD

    Recruiting

  • MCW-Clinical Cancer Center at Froedtert Hospital Campus

    Milwaukee, Wisconsin, 53226

    Binod Dhakal, MD

    Recruiting

  • Tennessee Oncology

    Nashville, Tennessee, 37203

    Jesus Berdeja, MD

    Recruiting

  • The Tisch Cancer Institute/Mount Sinai

    New York, New York, 10029

    Shambavi Richard, MD

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065

    Hamza Hashmi, MD

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Sarah Holstein, MD

    Recruiting

  • Mayo Clinic - Arizona

    Phoenix, Arizona, 85054

    Saurabh Chhabra, MD

    Recruiting

  • Mayo Clinic - Minnesota

    Rochester, Minnesota, 55905

    Wilson Gonsalves, MD

    Recruiting

  • START San Antonio

    San Antonio, Texas, 78229

    Kyriakos Papadopoulos, MD

    Recruiting

  • HonorHealth

    Scottsdale, Arizona, 85258

    Rizwan Khawaja, MD

    Recruiting

  • Washington University/Siteman Cancer Center

    St Louis, Missouri, 63108

    Mark Schroeder, MD

    Recruiting

  • Berenson Cancer Center

    West Hollywood, California, 90069

    James Berenson, MD

    Recruiting

Other trials in United States

Spain9 sites, 9 recruiting

  • Hospital Clínic de Barcelona

    Barcelona

    Laura Rosiñol Dachs, MD

    Not yet recruiting

  • Institut Catala d'Oncologia (ICO) Badalona - Hospital Germans Trias i Pujol

    Barcelona

    Gladys Ibarra Fernández, MD

    Not yet recruiting

  • Institut Català d'Oncologia (ICO) L'hospitalet

    Barcelona

    Itziar Carro Arostegui, MD

    Not yet recruiting

  • Hospital Clínico Universitario Virgen de la Arrixaca

    El Palmar

    Valentin Cabañas Perianes, MD

    Not yet recruiting

  • Hospital Universitario de Cabueñes

    Gijón

    Maria Esther Gonzalez Garcia, MD

    Not yet recruiting

  • Complejo Asistencial Universitario de León

    León

    Fernando Escalante-Barrigón, MD

    Not yet recruiting

  • Hospital Universitario HM Sanchinarro

    Madrid

    Luis Felipe Casado Montero, MD

    Not yet recruiting

  • Clinica Universidad de Navarra

    Pamplona

    Paula Rodríguez Otero, MD

    Not yet recruiting

  • Complejo Asistencial Universitario De Salamanca (CAUSA)

    Salamanca

    Maria Victoria Mateos Manteca, MD

    Not yet recruiting

Other trials in Spain

United Kingdom9 sites, 9 recruiting

  • NHS Lothian - Western General Hospital- Edinburgh Cancer Centre

    Edinburgh

    Victoria Campbell, MD

    Recruiting

  • The Leeds Teaching Hospitals NHS Trust - St James's University Hospital

    Leeds

    Christopher Parrish, MD

    Recruiting

  • Imperial College Healthcare NHS Foundation Trust - Hammersmith Hospital

    London, United Kingdom

    Aristeidis Chaidos, MD

    Recruiting

  • The King's College Hospital NHS Foundation Trust

    London

    Kirsty Cuthill, MD

    Recruiting

  • The Christie NHS Foundation Trust

    Manchester

    Emma Searle, MD

    Recruiting

  • Newcastle University Hospitals NHS Foundation Trust

    Newcastle upon Tyne

    Andrew Charlton, MD

    Recruiting

  • GenesisCare, Beaumont House

    Oxford

    Karthik Ramasamy, MD

    Not yet recruiting

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey

    Martin Kaiser, MD

    Recruiting

  • GenesisCare, Windsor

    Windsor

    Jaimal Kothari, MD

    Not yet recruiting

Other trials in United Kingdom

France7 sites, 7 recruiting

  • Centre Hospitalier de la Côte Basque

    Bayonne

    Julie Gay, MD

    Recruiting

  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud

    Lyon

    Lionel Karlin, MD

    Not yet recruiting

  • Institut Paoli-Calmettes (IPC)

    Marseille

    Jean-Marc Schiano de Colella, MD

    Not yet recruiting

  • Centre Henri-Becquerel

    Rouen

    Pascal Lenain, MD

    Not yet recruiting

  • Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)

    Toulouse

    Aurore Perrot, MD

    Not yet recruiting

  • Centre Hospitalier Regional et Universitaire de Tours (CHRU Tours) Hospital Bretonneau

    Tours

    Thomas Chalopin, MD

    Not yet recruiting

  • Institut Gustave Roussy

    Villejuif

    Vincent Ribrag, MD

    Not yet recruiting

Other trials in France

Italy6 sites, 6 recruiting

  • Servizio Sanitario Regionale Emilia-Romagna-Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" Srl

    Meldola

    Claudio Cerchione, MD

    Not yet recruiting

  • Azienda Ospedaliera Universitaria (AOU) "Federico II"

    Naples

    Fabrizio Pane, MD

    Not yet recruiting

  • Universita degli Studi di Pavia-Fondazione IRCCS Policlinico San Matteo

    Pavia

    Silvia Mangiacavalli, MD

    Not yet recruiting

  • Servizio Sanitario Regionale Emilia-Romagna - Ematologia Ospedale Infermi di Rimini

    Rimini

    Francesco Rotondo, MD

    Not yet recruiting

  • Azienda Sanitaria Locale (ASL) Roma 1 - Ospedale Santo Spirito

    Roma

    Tommaso Caravita di Toritto, MD

    Not yet recruiting

  • Ospedale Casa Sollievo della Sofferenza

    San Giovanni Rotondo

    Angelo Michele Carella, MD

    Recruiting

Other trials in Italy

Poland4 sites, 4 recruiting

  • IN-VIVO Sp.z.o.o

    Bydgoszcz

    Jaroslaw Czyz, MD

    Not yet recruiting

  • Uniwersyteckie Centrum Kliniczne w Gdańsku

    Gdansk

    Agata Tyczynska, MD

    Not yet recruiting

  • Pratia Hematologia Sp. Z o. o

    Katowice

    Sebastian Grosicki, MD

    Recruiting

  • Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu

    Wroclaw

    Tomasz Wrobel, MD

    Not yet recruiting

Other trials in Poland

About this study

Official title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

Being tested
Cemsidomide, Dexamethasone
Keywords
cemsidomide, dexamethasone, Multiple Myeloma
Medical subject headings
Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CemsidomideDrug

    dosed orally (PO) once a day (QD) 14 days on/14 days off for each 28-day cycle

  • DexamethasoneDrug

    dosed PO once a week (QW) on Days 1, 8, 15, and 22 for each 28-day cycle

Study groups in NCT07284758
Study groupRoleWhat they receive
Cemsidomide + Dexamethasone:ExperimentalParticipants receive cemsidomide plus dexamethasone during a 28-day treatment cycle, and will continue to receive treatment until the participant meets one of the discontinuation criteria.
Receives: Drug: Cemsidomide; Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC)

    Measured: up to approximately 43 months

Secondary outcomes (7)

  1. Duration of response (DoR; IRC assessed)

    Measured: up to approximately 43 months

  2. Complete response (CR) rate (IRC assessed)

    Measured: up to approximately 43 months

  3. Time to response (IRC assessed)

    Measured: up to approximately 43 months

  4. Progression free survival (PFS; IRC assessed)

    Measured: up to approximately 43 months

  5. Overall survival (OS)

    Measured: up to approximately 43 months

  6. Adverse events (AEs); serious AEs (SAEs); AEs leading to treatment interruption, reduction, or discontinuation; and deaths

    Measured: within 30 to 35 days of the last dose of study treatment

  7. Plasma concentrations of cemsidomide

    Measured: up to approximately 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2025
  2. Study start18 Feb 2026
  3. Primary completionMar 2030 (estimated)
  4. Study completionMar 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07284758
Sponsor's protocol ID
CFT7455-2101
Acronym
MOMENTUM
Status last verified
Sep 2026
First submitted
9 Dec 2025
Last updated
30 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Cemsidomide and Dexamethasone in people with Multiple Myeloma and Relapsed/Refractory Multiple Myeloma, run by C4 Therapeutics, Inc. at 60 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 60 sites in United States, Spain, United Kingdom, France, Italy and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Study Medical Officer ((617) 231-0700, clinicaltrials@c4therapeutics.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC) (time frame: up to approximately 43 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07284758.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in